摘要- canx: 2020年2月12日至13日,葡萄牙里斯本国际医用大麻大会

Q1 Medicine
C. Rundle, S. Dercon, P. Lio, J. Fernandez, M. Fujita, R. Dellavalle
{"title":"摘要- canx: 2020年2月12日至13日,葡萄牙里斯本国际医用大麻大会","authors":"C. Rundle, S. Dercon, P. Lio, J. Fernandez, M. Fujita, R. Dellavalle","doi":"10.1159/000505827","DOIUrl":null,"url":null,"abstract":"Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Reported cases of cancer in both genders are 18.78 million in 2018 with ap-proximately 70% of deaths occurring in low- and middle-income countries, including Pakistan. Breast cancer is the highest reported cancer in Pakistan while prostate cancer constitutes 6.7% of the total cancer burden. Anti-cancer activity of selected plant-derived cannabinoids has been studied in different cancer cell lines showing positive results by some investigators but there is no such report available from Pakistan and the therapeutic potential of Pakistani varieties of Cannabis Sativa remains unexplored. We infer that the variant of C. sativa cultivated in Pakistan is efficacious against human breast cancer and prostate cancer cell lines. This study is planned to evaluate the anticancer properties of different extracts (Flowers, leaves, stem, root, seeds and whole plant extracts) of Cannabis Sativa cultivated in Pakistan against human breast cancer cell lines (MCF-7 and MDA-MB-231) and prostate cancer cell lines (PC3 and LNCaP). All plant material will be dry and powdered in pharmacology laboratory. Each plant material will be soaked in aqueous methanol (30:70) for three days at room temperature and 1st, 2nd, and 3rd filtrates will be obtained using a muslin cloth and Whatman filter paper. The filtrates will be com-bined together and solvent will be removed using a rotary-evapo-rator under reduced pressure, to yield/obtained respective Cannabis sativa thick extract. An intramural grant has been procured for this study. Results will be shared during the research presentation. Delta-9-tetrahydrocannabinol (THC) is the main phytocan-nabinoid in “Cannabis sativa”. Cannabis use by pregnant women to relieve morning sickness has been increasing, as reported by various epidemiological studies. Diverse processes are involved in the remodelling of trophoblast cells, such as proliferation, differentiation, apoptosis and invasion, which are crucial for placental development. The consumption of cannabis during pregnancy is of much concern since it may disrupt the endocannabinoid system (ECS) which modulates several biological functions, including re-production. Our group demonstrated that THC has an impact on trophoblast turnover, through induction of apoptosis, as well as on the ECS homeostasis. Considering the relevance of cannabinoid signalling in reproductive tissues, women of child-bearing age may be a particularly sensitive group to cannabinoids exposure. Thus, it is important to understand the consequences of this exposure on reproductive health. The aim of this work was to study the effects of THC on trophoblast cells, using BeWo and HTR-8 (ATCC, USA) cell lines, well-accepted models of cytotrophoblasts (“stem cells”) and extravillous/invasive trophoblasts, respectively. It was observed that THC induces a dose-dependent decrease in cell vi-ability although at lower concentrations in the case of HTR-8 cells. Results indicate that THC may affect trophoblast cells remodelling by apoptosis activation. Moreover, this cannabinoid affects the invasive properties of extravillous trophoblasts. build and strengthen C4T in preparation for the successful design and conduct of future randomized controlled trials to evaluate the effectiveness of cannabis in children, starting with childhood cancers. Updates from C4T will be provided by our Scientific Director on our parent-resource hub, surveillance studies, observational studies on cannabis pharmacodynamics and pharmacokinetics in children with cancer and our open-label dosing study on a cannabis health product for symptom management in children with cancer. This session will also discuss practical considerations for operating cannabis clinical trials with children including ethical considerations, funding models and academic part-nerships. (knowl-edge, find Methodology: After ethics review committee approval, anesthesiologists working in centers that provide management will through to fill an online KAP survey. This survey will contain questions relevant to the knowledge about; available preparations of Cannabis, legality of use in the country, indications and contraindications, side effects, Attitude; willingness to use if available, barriers to use, and Practice; their experience of using medical Cannabis. Survey will be administered through Google forms. Selected participants will be sent a reminder after 10 days of the first email, and a second reminder after 20 days. Data will be analyzed by Statistical packages for social science version 17 (SPSS Mean and standard deviation will be computed for age and experience of anesthesiologist. Frequency and percentage will be computed for gender, knowledge, attitude and perception of Pakistani anesthesiologists about medical of cannabis. Chi-square test or Fisher exact test will be used at p ≤ 0.05 of The endocannabinoid system (ECS) is composed by the cannabinoid receptors CB1 and CB2, their main endogenous ligands N -arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) as their main metabolic enzymes of synthesis and degradation: N -acylphosphatidylethanolamide-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH) for AEA and diacylglycerol lipase (DAGL) and monoacylglycerol lipase (MAGL) for 2-AG. Among the physiological functions modulat-ed by the ECS, the reproductive one has been a hot topic, given the importance of a tight regulation of the endocannabinoid levels on decidualization and placentation. Moreover, the increase in cannabis consumption by woman during gestation has led to pour pregnancy outcomes such as low birth weight, prematurity and intrauterine growth restriction. These effects may be due to the main psychoactive compound of cannabis, Tetrahydrocannabinol (THC), since, even though it is hard to prove its effect in cannabis consumers, given the plethora of compounds present in the plant, we recently presented evidence that THC impairs the AEA levels and its metabolic enzymes in placental explants. To provide a better understand of the biochemical mechanisms behind these pour outcomes, we studied the impact of THC in 2-AG metabolism by quantification of its levels and expression of its main metabolic enzymes DAGL and MAGL in placental explants. Our results showed that both DAGL and MAGL are present in the placental explants in the syncytiotrophoblast layer. THC caused an increase in both DAGL and MAGL after short periods, a decrease in MAGL expression was observed for longer periods of incubation. However, 2-AG levels remained unchanged in both periods of culture, the 2-AG levels may be controlled by other mechanisms that under evaluation. Autism Spectrum Disorders comprise conditions that may affect In this study the steam extracted pure essential oil of hemp ( Cannabis sativa L) as well as its different fractions, obtained by fractional distillation of oil, were analyzed using Raman spectroscopy coupled with the Principal Component Analysis (PCA), a multivariate data analysis technique. The most important features observed in the Raman spectra are used to identify the presence of different components in the pure hemp oil as well as in its different fractions. These Raman spectral features can be considered as markers to provide information about the chemical composition of the hemp essential oil. Principal Component analysis (PCA) is employed to identify the biochemical features responsible for the differentiation between different fractions of hemp essential oil. Hepatoprotective activity of Cannabis sativa (Hemp) essential oil and its different fractions was studied using a carbon tetrachloride induced liver fibrosis model in rats. The hepatotoxicity produced by chronic carbon tetrachloride administration was found to be inhibited by Cannabis sativa essential oil and its different fractions with the evidence of decreased levels of serum aspartate amino-transferase, alanine aminotransferase, alkaline phosphatase and bilirubin. The histopathological findings also suggest that Cannabis sativa essential oil prevents the development of chronic liver damage. The changes in the body weights in the rats assigned to the study groups supported these biochemical and histopathological findings. The results of this study clearly indicate that Cannabis sativa essential oil and its five different fractions have a potent hepatoprotective action against carbon tetrachloride-induced liver fibrosis in rats. The fraction-5 was found to have maximum per-centage/concentration of the active component of β-carophyllene Medical cannabis usage has spread over the last few years in jurisdictions were it has been permitted, despite the plant being defined as a schedule one drug. Due to a fairly large body of evidence demonstrating possible amelioration of neuropathy symptoms following cannabis usage, this indication is currently approved in our nation. Patients must undergo a minimum of 12 months treatment by other medications in a pain clinic. The current cohort is a sequential cohort of 89 diabetic patients who failed a minimal 12 months course of drug therapy. The patients were treated by at least three drugs prior to instigation of medical cannabis therapy. The cannabis therapy was a smoked preparation with a minimal THC content of 10 percent and minimal CBD content of 2 percent. The dose was increased as necessary after a minimum of 3 months of therapy. Prior to therapy the patients had performed the following blood tests: hsCRP, total cholesterol, non-HDL cholesterol, HDL and complete blood count. These tests were repeated after 12 months of therapy. The primary outcome measure was the NRS and it declined from 8.7 ± 1.1 to 4.1 ± 3.1 post 24 months cannabis therapy. The BPI score decreased from 7.8 ± 2 to 2.9 ± 1. The CRP averaged 1.4 ± 0.8 and decreased to 0.6 ± 0.3. Hemoglobin levels did not change. W","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"3 1","pages":"116 - 131"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000505827","citationCount":"0","resultStr":"{\"title\":\"Abstracts - CannX: The International Medical Cannabis Conference Lisbon, Portugal, February 12-13, 2020\",\"authors\":\"C. Rundle, S. Dercon, P. Lio, J. Fernandez, M. Fujita, R. Dellavalle\",\"doi\":\"10.1159/000505827\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Reported cases of cancer in both genders are 18.78 million in 2018 with ap-proximately 70% of deaths occurring in low- and middle-income countries, including Pakistan. Breast cancer is the highest reported cancer in Pakistan while prostate cancer constitutes 6.7% of the total cancer burden. Anti-cancer activity of selected plant-derived cannabinoids has been studied in different cancer cell lines showing positive results by some investigators but there is no such report available from Pakistan and the therapeutic potential of Pakistani varieties of Cannabis Sativa remains unexplored. We infer that the variant of C. sativa cultivated in Pakistan is efficacious against human breast cancer and prostate cancer cell lines. This study is planned to evaluate the anticancer properties of different extracts (Flowers, leaves, stem, root, seeds and whole plant extracts) of Cannabis Sativa cultivated in Pakistan against human breast cancer cell lines (MCF-7 and MDA-MB-231) and prostate cancer cell lines (PC3 and LNCaP). All plant material will be dry and powdered in pharmacology laboratory. Each plant material will be soaked in aqueous methanol (30:70) for three days at room temperature and 1st, 2nd, and 3rd filtrates will be obtained using a muslin cloth and Whatman filter paper. The filtrates will be com-bined together and solvent will be removed using a rotary-evapo-rator under reduced pressure, to yield/obtained respective Cannabis sativa thick extract. An intramural grant has been procured for this study. Results will be shared during the research presentation. Delta-9-tetrahydrocannabinol (THC) is the main phytocan-nabinoid in “Cannabis sativa”. Cannabis use by pregnant women to relieve morning sickness has been increasing, as reported by various epidemiological studies. Diverse processes are involved in the remodelling of trophoblast cells, such as proliferation, differentiation, apoptosis and invasion, which are crucial for placental development. The consumption of cannabis during pregnancy is of much concern since it may disrupt the endocannabinoid system (ECS) which modulates several biological functions, including re-production. Our group demonstrated that THC has an impact on trophoblast turnover, through induction of apoptosis, as well as on the ECS homeostasis. Considering the relevance of cannabinoid signalling in reproductive tissues, women of child-bearing age may be a particularly sensitive group to cannabinoids exposure. Thus, it is important to understand the consequences of this exposure on reproductive health. The aim of this work was to study the effects of THC on trophoblast cells, using BeWo and HTR-8 (ATCC, USA) cell lines, well-accepted models of cytotrophoblasts (“stem cells”) and extravillous/invasive trophoblasts, respectively. It was observed that THC induces a dose-dependent decrease in cell vi-ability although at lower concentrations in the case of HTR-8 cells. Results indicate that THC may affect trophoblast cells remodelling by apoptosis activation. Moreover, this cannabinoid affects the invasive properties of extravillous trophoblasts. build and strengthen C4T in preparation for the successful design and conduct of future randomized controlled trials to evaluate the effectiveness of cannabis in children, starting with childhood cancers. Updates from C4T will be provided by our Scientific Director on our parent-resource hub, surveillance studies, observational studies on cannabis pharmacodynamics and pharmacokinetics in children with cancer and our open-label dosing study on a cannabis health product for symptom management in children with cancer. This session will also discuss practical considerations for operating cannabis clinical trials with children including ethical considerations, funding models and academic part-nerships. (knowl-edge, find Methodology: After ethics review committee approval, anesthesiologists working in centers that provide management will through to fill an online KAP survey. This survey will contain questions relevant to the knowledge about; available preparations of Cannabis, legality of use in the country, indications and contraindications, side effects, Attitude; willingness to use if available, barriers to use, and Practice; their experience of using medical Cannabis. Survey will be administered through Google forms. Selected participants will be sent a reminder after 10 days of the first email, and a second reminder after 20 days. Data will be analyzed by Statistical packages for social science version 17 (SPSS Mean and standard deviation will be computed for age and experience of anesthesiologist. Frequency and percentage will be computed for gender, knowledge, attitude and perception of Pakistani anesthesiologists about medical of cannabis. Chi-square test or Fisher exact test will be used at p ≤ 0.05 of The endocannabinoid system (ECS) is composed by the cannabinoid receptors CB1 and CB2, their main endogenous ligands N -arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) as their main metabolic enzymes of synthesis and degradation: N -acylphosphatidylethanolamide-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH) for AEA and diacylglycerol lipase (DAGL) and monoacylglycerol lipase (MAGL) for 2-AG. Among the physiological functions modulat-ed by the ECS, the reproductive one has been a hot topic, given the importance of a tight regulation of the endocannabinoid levels on decidualization and placentation. Moreover, the increase in cannabis consumption by woman during gestation has led to pour pregnancy outcomes such as low birth weight, prematurity and intrauterine growth restriction. These effects may be due to the main psychoactive compound of cannabis, Tetrahydrocannabinol (THC), since, even though it is hard to prove its effect in cannabis consumers, given the plethora of compounds present in the plant, we recently presented evidence that THC impairs the AEA levels and its metabolic enzymes in placental explants. To provide a better understand of the biochemical mechanisms behind these pour outcomes, we studied the impact of THC in 2-AG metabolism by quantification of its levels and expression of its main metabolic enzymes DAGL and MAGL in placental explants. Our results showed that both DAGL and MAGL are present in the placental explants in the syncytiotrophoblast layer. THC caused an increase in both DAGL and MAGL after short periods, a decrease in MAGL expression was observed for longer periods of incubation. However, 2-AG levels remained unchanged in both periods of culture, the 2-AG levels may be controlled by other mechanisms that under evaluation. Autism Spectrum Disorders comprise conditions that may affect In this study the steam extracted pure essential oil of hemp ( Cannabis sativa L) as well as its different fractions, obtained by fractional distillation of oil, were analyzed using Raman spectroscopy coupled with the Principal Component Analysis (PCA), a multivariate data analysis technique. The most important features observed in the Raman spectra are used to identify the presence of different components in the pure hemp oil as well as in its different fractions. These Raman spectral features can be considered as markers to provide information about the chemical composition of the hemp essential oil. Principal Component analysis (PCA) is employed to identify the biochemical features responsible for the differentiation between different fractions of hemp essential oil. Hepatoprotective activity of Cannabis sativa (Hemp) essential oil and its different fractions was studied using a carbon tetrachloride induced liver fibrosis model in rats. The hepatotoxicity produced by chronic carbon tetrachloride administration was found to be inhibited by Cannabis sativa essential oil and its different fractions with the evidence of decreased levels of serum aspartate amino-transferase, alanine aminotransferase, alkaline phosphatase and bilirubin. The histopathological findings also suggest that Cannabis sativa essential oil prevents the development of chronic liver damage. The changes in the body weights in the rats assigned to the study groups supported these biochemical and histopathological findings. The results of this study clearly indicate that Cannabis sativa essential oil and its five different fractions have a potent hepatoprotective action against carbon tetrachloride-induced liver fibrosis in rats. The fraction-5 was found to have maximum per-centage/concentration of the active component of β-carophyllene Medical cannabis usage has spread over the last few years in jurisdictions were it has been permitted, despite the plant being defined as a schedule one drug. Due to a fairly large body of evidence demonstrating possible amelioration of neuropathy symptoms following cannabis usage, this indication is currently approved in our nation. Patients must undergo a minimum of 12 months treatment by other medications in a pain clinic. The current cohort is a sequential cohort of 89 diabetic patients who failed a minimal 12 months course of drug therapy. The patients were treated by at least three drugs prior to instigation of medical cannabis therapy. The cannabis therapy was a smoked preparation with a minimal THC content of 10 percent and minimal CBD content of 2 percent. The dose was increased as necessary after a minimum of 3 months of therapy. Prior to therapy the patients had performed the following blood tests: hsCRP, total cholesterol, non-HDL cholesterol, HDL and complete blood count. These tests were repeated after 12 months of therapy. The primary outcome measure was the NRS and it declined from 8.7 ± 1.1 to 4.1 ± 3.1 post 24 months cannabis therapy. The BPI score decreased from 7.8 ± 2 to 2.9 ± 1. The CRP averaged 1.4 ± 0.8 and decreased to 0.6 ± 0.3. Hemoglobin levels did not change. W\",\"PeriodicalId\":18415,\"journal\":{\"name\":\"Medical Cannabis and Cannabinoids\",\"volume\":\"3 1\",\"pages\":\"116 - 131\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000505827\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Cannabis and Cannabinoids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000505827\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000505827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

癌症是全球第二大死因,2018年造成约960万人死亡。2018年,报告的男女癌症病例为1878万例,其中约70%的死亡发生在包括巴基斯坦在内的低收入和中等收入国家。乳腺癌是巴基斯坦报告的最高癌症,而前列腺癌占癌症总负担的6.7%。一些研究人员已经在不同的癌细胞系中研究了选定的植物来源的大麻素的抗癌活性,显示出积极的结果,但巴基斯坦没有这样的报告,巴基斯坦大麻品种的治疗潜力仍未得到探索。我们推断,在巴基斯坦栽培的苜蓿变种对人类乳腺癌和前列腺癌细胞系有效。本研究拟评估在巴基斯坦种植的大麻不同提取物(花、叶、茎、根、种子和全植物提取物)对人乳腺癌细胞系(MCF-7和MDA-MB-231)和前列腺癌细胞系(PC3和LNCaP)的抗癌特性。所有的植物材料都将在药理学实验室中干燥和粉末化。每种植物材料将在室温下在水溶液甲醇(30:70)中浸泡三天,并使用薄布和Whatman滤纸获得第一,第二和第三滤液。滤液将结合在一起,溶剂将在减压下使用旋转蒸发器去除,以产生/获得各自的大麻粗提取物。已经为这项研究获得了一笔校内赠款。结果将在研究报告中分享。δ -9-四氢大麻酚(THC)是“大麻”中的主要植物大麻素。根据各种流行病学研究报告,孕妇使用大麻缓解孕吐的情况正在增加。滋养层细胞的重塑涉及多种过程,如增殖、分化、凋亡和侵袭,这些过程对胎盘发育至关重要。怀孕期间吸食大麻是非常令人担忧的,因为它可能会破坏内源性大麻素系统(ECS),该系统调节包括生殖在内的几种生物功能。我们的研究小组证明,THC通过诱导细胞凋亡影响滋养细胞的周转,并影响ECS的稳态。考虑到大麻素信号在生殖组织中的相关性,育龄妇女可能是对大麻素暴露特别敏感的群体。因此,必须了解这种接触对生殖健康的影响。这项工作的目的是研究四氢大麻酚对滋养细胞的影响,使用BeWo和HTR-8 (ATCC, USA)细胞系,分别是公认的细胞滋养细胞模型(“干细胞”)和外渗/侵袭性滋养细胞。观察到THC诱导HTR-8细胞可见性呈剂量依赖性降低,尽管浓度较低。结果表明,四氢大麻酚可能通过激活细胞凋亡影响滋养细胞的重塑。此外,这种大麻素影响胞外滋养细胞的侵袭性。建立和加强C4T,为成功设计和开展未来的随机对照试验做准备,以评估大麻对儿童的有效性,从儿童癌症开始。C4T的最新信息将由我们的科学主任提供,内容包括我们的家长资源中心、监测研究、关于癌症儿童大麻药效学和药代动力学的观察性研究,以及我们关于用于癌症儿童症状管理的大麻保健品的开放标签剂量研究。本次会议还将讨论对儿童进行大麻临床试验的实际考虑,包括道德考虑、筹资模式和学术伙伴关系。在伦理审查委员会批准后,在提供管理的中心工作的麻醉师将通过填写在线KAP调查。这个调查将包含与知识有关的问题;可获得的大麻制剂、在该国使用的合法性、适应症和禁忌症、副作用、态度;如果可以使用,使用的意愿,使用的障碍和实践;他们使用医用大麻的经历调查将通过谷歌表格进行。被选中的参与者将在第一封邮件发出10天后收到提醒,并在20天后收到第二次提醒。数据将通过统计软件包社会科学版17 (SPSS平均和标准偏差将计算年龄和经验的麻醉师进行分析。将计算巴基斯坦麻醉师的性别、对医用大麻的知识、态度和看法的频率和百分比。在p≤0时采用卡方检验或Fisher精确检验。 内源性大麻素系统(ECS)由大麻素受体CB1和CB2组成,其主要内源性配体N -花生四烯醇乙醇胺(AEA)和2-花生四烯醇甘油(2-AG)作为其合成和降解的主要代谢酶:N -酰基磷脂酰乙醇酰胺特异性磷脂酶D (NAPE-PLD)和脂肪酸酰胺水解酶(FAAH)用于AEA,二酰基甘油脂肪酶(DAGL)和单酰基甘油脂肪酶(MAGL)用于2-AG。在ECS调节的生理功能中,由于内源性大麻素水平的严格调节对去个体化和胎盘的重要性,生殖功能一直是人们关注的热点。此外,妇女在怀孕期间大麻消费的增加导致了许多怀孕结果,如出生体重低、早产和宫内生长受限。这些影响可能是由于大麻的主要精神活性化合物四氢大麻酚(THC),因为尽管很难证明其对大麻消费者的影响,但考虑到植物中存在的大量化合物,我们最近提出的证据表明,THC会损害胎盘外植体中的AEA水平及其代谢酶。为了更好地了解这些结果背后的生化机制,我们通过量化胎盘外植体中THC的水平及其主要代谢酶DAGL和MAGL的表达,研究了THC对2-AG代谢的影响。结果表明,DAGL和MAGL均存在于胎盘外植体的合体滋养层中。四氢大麻酚在短时间内引起DAGL和MAGL的升高,在较长时间的孵育中观察到MAGL表达的降低。然而,2-AG水平在两个培养阶段都保持不变,2-AG水平可能受到其他机制的控制,目前尚在评估中。本研究采用多变量数据分析技术——拉曼光谱结合主成分分析(PCA),对蒸汽提取的大麻纯精油及其不同馏分进行了分析。在拉曼光谱中观察到的最重要的特征用于识别纯大麻油及其不同馏分中不同成分的存在。这些拉曼光谱特征可以被认为是提供大麻精油化学成分信息的标记。采用主成分分析(PCA)对大麻精油不同组分之间的生物化学特征进行鉴别。采用四氯化碳诱导大鼠肝纤维化模型,研究了大麻精油及其不同组分的保肝作用。结果表明,大麻油及其不同组分可抑制慢性四氯化碳给药所致的肝毒性,降低血清天冬氨酸转氨酶、丙氨酸转氨酶、碱性磷酸酶和胆红素水平。组织病理学结果还表明,大麻精油可以防止慢性肝损伤的发展。被分配到研究组的大鼠体重的变化支持了这些生化和组织病理学的发现。本研究结果清楚地表明,大麻精油及其5种不同组分对四氯化碳诱导的大鼠肝纤维化具有有效的保肝作用。在过去几年中,尽管医用大麻被定义为附表1药物,但在允许使用医用大麻的司法管辖区,医用大麻的使用已经普及。由于相当多的证据表明大麻使用后可能改善神经病变症状,这一适应症目前在我国得到批准。患者必须在疼痛诊所接受至少12个月的其他药物治疗。目前的队列是89例至少12个月药物治疗失败的糖尿病患者的顺序队列。患者在唆使进行医用大麻治疗之前至少接受了三种药物治疗。大麻疗法是一种烟熏制剂,最低THC含量为10%,最低CBD含量为2%。治疗至少3个月后,剂量根据需要增加。治疗前,患者进行了以下血液检查:hsCRP、总胆固醇、非高密度脂蛋白胆固醇、高密度脂蛋白和全血细胞计数。这些测试在治疗12个月后重复进行。主要结局指标为NRS,大麻治疗24个月后,NRS从8.7±1.1降至4.1±3.1。BPI评分由7.8±2降至2.9±1。CRP平均值为1.4±0.8,降至0.6±0。 3.血红蛋白水平没有变化。W
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Abstracts - CannX: The International Medical Cannabis Conference Lisbon, Portugal, February 12-13, 2020
Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Reported cases of cancer in both genders are 18.78 million in 2018 with ap-proximately 70% of deaths occurring in low- and middle-income countries, including Pakistan. Breast cancer is the highest reported cancer in Pakistan while prostate cancer constitutes 6.7% of the total cancer burden. Anti-cancer activity of selected plant-derived cannabinoids has been studied in different cancer cell lines showing positive results by some investigators but there is no such report available from Pakistan and the therapeutic potential of Pakistani varieties of Cannabis Sativa remains unexplored. We infer that the variant of C. sativa cultivated in Pakistan is efficacious against human breast cancer and prostate cancer cell lines. This study is planned to evaluate the anticancer properties of different extracts (Flowers, leaves, stem, root, seeds and whole plant extracts) of Cannabis Sativa cultivated in Pakistan against human breast cancer cell lines (MCF-7 and MDA-MB-231) and prostate cancer cell lines (PC3 and LNCaP). All plant material will be dry and powdered in pharmacology laboratory. Each plant material will be soaked in aqueous methanol (30:70) for three days at room temperature and 1st, 2nd, and 3rd filtrates will be obtained using a muslin cloth and Whatman filter paper. The filtrates will be com-bined together and solvent will be removed using a rotary-evapo-rator under reduced pressure, to yield/obtained respective Cannabis sativa thick extract. An intramural grant has been procured for this study. Results will be shared during the research presentation. Delta-9-tetrahydrocannabinol (THC) is the main phytocan-nabinoid in “Cannabis sativa”. Cannabis use by pregnant women to relieve morning sickness has been increasing, as reported by various epidemiological studies. Diverse processes are involved in the remodelling of trophoblast cells, such as proliferation, differentiation, apoptosis and invasion, which are crucial for placental development. The consumption of cannabis during pregnancy is of much concern since it may disrupt the endocannabinoid system (ECS) which modulates several biological functions, including re-production. Our group demonstrated that THC has an impact on trophoblast turnover, through induction of apoptosis, as well as on the ECS homeostasis. Considering the relevance of cannabinoid signalling in reproductive tissues, women of child-bearing age may be a particularly sensitive group to cannabinoids exposure. Thus, it is important to understand the consequences of this exposure on reproductive health. The aim of this work was to study the effects of THC on trophoblast cells, using BeWo and HTR-8 (ATCC, USA) cell lines, well-accepted models of cytotrophoblasts (“stem cells”) and extravillous/invasive trophoblasts, respectively. It was observed that THC induces a dose-dependent decrease in cell vi-ability although at lower concentrations in the case of HTR-8 cells. Results indicate that THC may affect trophoblast cells remodelling by apoptosis activation. Moreover, this cannabinoid affects the invasive properties of extravillous trophoblasts. build and strengthen C4T in preparation for the successful design and conduct of future randomized controlled trials to evaluate the effectiveness of cannabis in children, starting with childhood cancers. Updates from C4T will be provided by our Scientific Director on our parent-resource hub, surveillance studies, observational studies on cannabis pharmacodynamics and pharmacokinetics in children with cancer and our open-label dosing study on a cannabis health product for symptom management in children with cancer. This session will also discuss practical considerations for operating cannabis clinical trials with children including ethical considerations, funding models and academic part-nerships. (knowl-edge, find Methodology: After ethics review committee approval, anesthesiologists working in centers that provide management will through to fill an online KAP survey. This survey will contain questions relevant to the knowledge about; available preparations of Cannabis, legality of use in the country, indications and contraindications, side effects, Attitude; willingness to use if available, barriers to use, and Practice; their experience of using medical Cannabis. Survey will be administered through Google forms. Selected participants will be sent a reminder after 10 days of the first email, and a second reminder after 20 days. Data will be analyzed by Statistical packages for social science version 17 (SPSS Mean and standard deviation will be computed for age and experience of anesthesiologist. Frequency and percentage will be computed for gender, knowledge, attitude and perception of Pakistani anesthesiologists about medical of cannabis. Chi-square test or Fisher exact test will be used at p ≤ 0.05 of The endocannabinoid system (ECS) is composed by the cannabinoid receptors CB1 and CB2, their main endogenous ligands N -arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) as their main metabolic enzymes of synthesis and degradation: N -acylphosphatidylethanolamide-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH) for AEA and diacylglycerol lipase (DAGL) and monoacylglycerol lipase (MAGL) for 2-AG. Among the physiological functions modulat-ed by the ECS, the reproductive one has been a hot topic, given the importance of a tight regulation of the endocannabinoid levels on decidualization and placentation. Moreover, the increase in cannabis consumption by woman during gestation has led to pour pregnancy outcomes such as low birth weight, prematurity and intrauterine growth restriction. These effects may be due to the main psychoactive compound of cannabis, Tetrahydrocannabinol (THC), since, even though it is hard to prove its effect in cannabis consumers, given the plethora of compounds present in the plant, we recently presented evidence that THC impairs the AEA levels and its metabolic enzymes in placental explants. To provide a better understand of the biochemical mechanisms behind these pour outcomes, we studied the impact of THC in 2-AG metabolism by quantification of its levels and expression of its main metabolic enzymes DAGL and MAGL in placental explants. Our results showed that both DAGL and MAGL are present in the placental explants in the syncytiotrophoblast layer. THC caused an increase in both DAGL and MAGL after short periods, a decrease in MAGL expression was observed for longer periods of incubation. However, 2-AG levels remained unchanged in both periods of culture, the 2-AG levels may be controlled by other mechanisms that under evaluation. Autism Spectrum Disorders comprise conditions that may affect In this study the steam extracted pure essential oil of hemp ( Cannabis sativa L) as well as its different fractions, obtained by fractional distillation of oil, were analyzed using Raman spectroscopy coupled with the Principal Component Analysis (PCA), a multivariate data analysis technique. The most important features observed in the Raman spectra are used to identify the presence of different components in the pure hemp oil as well as in its different fractions. These Raman spectral features can be considered as markers to provide information about the chemical composition of the hemp essential oil. Principal Component analysis (PCA) is employed to identify the biochemical features responsible for the differentiation between different fractions of hemp essential oil. Hepatoprotective activity of Cannabis sativa (Hemp) essential oil and its different fractions was studied using a carbon tetrachloride induced liver fibrosis model in rats. The hepatotoxicity produced by chronic carbon tetrachloride administration was found to be inhibited by Cannabis sativa essential oil and its different fractions with the evidence of decreased levels of serum aspartate amino-transferase, alanine aminotransferase, alkaline phosphatase and bilirubin. The histopathological findings also suggest that Cannabis sativa essential oil prevents the development of chronic liver damage. The changes in the body weights in the rats assigned to the study groups supported these biochemical and histopathological findings. The results of this study clearly indicate that Cannabis sativa essential oil and its five different fractions have a potent hepatoprotective action against carbon tetrachloride-induced liver fibrosis in rats. The fraction-5 was found to have maximum per-centage/concentration of the active component of β-carophyllene Medical cannabis usage has spread over the last few years in jurisdictions were it has been permitted, despite the plant being defined as a schedule one drug. Due to a fairly large body of evidence demonstrating possible amelioration of neuropathy symptoms following cannabis usage, this indication is currently approved in our nation. Patients must undergo a minimum of 12 months treatment by other medications in a pain clinic. The current cohort is a sequential cohort of 89 diabetic patients who failed a minimal 12 months course of drug therapy. The patients were treated by at least three drugs prior to instigation of medical cannabis therapy. The cannabis therapy was a smoked preparation with a minimal THC content of 10 percent and minimal CBD content of 2 percent. The dose was increased as necessary after a minimum of 3 months of therapy. Prior to therapy the patients had performed the following blood tests: hsCRP, total cholesterol, non-HDL cholesterol, HDL and complete blood count. These tests were repeated after 12 months of therapy. The primary outcome measure was the NRS and it declined from 8.7 ± 1.1 to 4.1 ± 3.1 post 24 months cannabis therapy. The BPI score decreased from 7.8 ± 2 to 2.9 ± 1. The CRP averaged 1.4 ± 0.8 and decreased to 0.6 ± 0.3. Hemoglobin levels did not change. W
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信